Fabry treatment study reveals hidden time and cost burdens on patients and caregivers

NCT ID NCT04281537

First seen Feb 05, 2026 · Last updated Jun 15, 2026 · Updated 19 times

Summary

This study looked at how enzyme replacement therapy (ERT) for Fabry disease affects the daily lives of patients, their caregivers, and healthcare providers. Researchers measured the time spent preparing and giving the treatment, as well as its impact on patient quality of life, fatigue, and work productivity. The goal was to better understand the real-world experience of managing this rare disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Amicus Therapeutics, Inc.

    Philadelphia, Pennsylvania, 19104, United States

  • Dokuz Eylul University Medical Faculty

    Izmir, Turkey (Türkiye)

  • Ege University Hospital

    Izmir, Turkey (Türkiye)

  • Gazi University Hospital

    Ankara, Turkey (Türkiye)

  • Instituto de Genética e Erros Inatos do Metabolismo (IGEIM)

    São Paulo, Brazil

  • Keio University Hospital

    Tokyo, Japan

  • National Taiwan University

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Yokohama Municipal Citizen's Hospital

    Yokohama, Japan

Conditions

Explore the condition pages connected to this study.